Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 5,280,000 shares, a decrease of 14.6% from the October 15th total of 6,180,000 shares. Based on an average daily volume of 2,990,000 shares, the days-to-cover ratio is currently 1.8 days.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CAPR. Piper Sandler started coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Cantor Fitzgerald upped their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday. Maxim Group upped their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Trading Up 0.6 %

Shares of Capricor Therapeutics stock traded up $0.12 during trading on Friday, reaching $18.61. The company’s stock had a trading volume of 929,811 shares, compared to its average volume of 1,344,771. The company has a 50-day moving average price of $15.21 and a two-hundred day moving average price of $8.48. Capricor Therapeutics has a fifty-two week low of $2.87 and a fifty-two week high of $23.40. The firm has a market cap of $845.01 million, a PE ratio of -17.56 and a beta of 4.00.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CAPR. Point72 Asset Management L.P. purchased a new position in shares of Capricor Therapeutics during the third quarter worth about $3,806,000. Vanguard Group Inc. lifted its position in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after acquiring an additional 200,499 shares during the period. PFM Health Sciences LP purchased a new position in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $2,324,000. State Street Corp grew its stake in shares of Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after purchasing an additional 111,291 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the second quarter valued at approximately $426,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.